HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AFL

AFLAC Incorporated (S&P 500)

Financial Services — Insurance - Life

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.

Hold 3.1 / 5 14 analysts
$129.55
+$2.99 (+2.36%)
Target: $117.71 (-9.1%)
Sign in to add AFL to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$65.94B
P/E Ratio (TTM)14.81
Forward P/E17.17
EPS (TTM)$8.75
Dividend Yield1.93%
Profit Margin25.60%
Revenue Growth27.90%
ROE16.47%
Debt/Equity48.28
Recommendation Hold 3.1
Analyst Target$117.71
Analysts14
Indexes S&P 500

Technical Indicators

RSI (14)76.8
Beta0.60
SMA 20$122.77
SMA 40$119.72
52-Week High$129.62
52-Week Low$96.95
50-Day Avg$118.79
200-Day Avg$112.99
Avg Volume$2.46M
Volume$1.34M

Performance Analysis

NEUTRAL

AFL presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($129.62), which may indicate limited upside.
- RSI at 76.8 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ P/E of 14.8 suggests the stock may be undervalued.
+ Strong revenue growth of 27.9% year-over-year.
+ Healthy profit margin of 25.6%.
~ Wall Street consensus is "Hold" from 14 analysts.
- Average analyst target of $117.71 implies 9.1% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report